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Objectives:  To  assess  the  level  of  fecal  calprotectin  in  preterm  neonates  with  feeding  intoler-
ance, as  well  as  to  evaluate  it  as  a  marker  of  feeding  intolerance  and  to  determine  a  cut-off
level of  fecal  calprotectin  in  feeding  intolerance.
Methods:  Analytical,  multicenter,  case--control  study,  which  was  carried  out  in  neonatal  inten-
sive care  units  in  Egypt,  in  a  period  from  August  1,  2014  to  March  1,  2015  on  52  preterm
neonates.  Neonates  were  classiﬁed  into  two  groups;  a  study  group  including  26  neonates  who
met inclusion  criteria  and  a  control  group  including  26  neonates  for  comparison.
Results:  Fecal  calprotectin  levels  ranged  from  3.9  g/g  to  971.8  g/g,  and  there  was  a  signif-
icant increase  in  fecal  calprotectin  in  the  study  group  when  compared  to  the  control  group
(334.3 ±  236.6  g/g  vs.  42.0  ±  38.2  g/g,  respectively)  with  moderate  inverse  signiﬁcant  cor-
relation between  fecal  calprotectin  and  birth  weight.  Furthermore,  there  was  moderate,
signiﬁcant  correlation  between  fecal  calprotectin  and  duration  of  breastfeeding  range.  On  the
other hand,  there  was  no  correlation  between  fecal  calprotectin  and  post-natal  age,  gestational
age, or  volume  of  feeding.  A  cut-off  at  the  67.0  g/g  level,  with  100.0%  sensitivity  and  76.9%
speciﬁcity, was  considered.
Conclusion:  Fecal  calprotectin  level  increased  signiﬁcantly  in  neonates  with  feeding  intoler-
ance; it  can  be  used  to  detect  early  cases  with  necrotizing  enterocolitis  in  neonates,  but  this
subject still  needs  more  investigations  on  more  patients.
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Níveis  de  calprotectina  fecal  em  neonatos  prematuros  com  e  sem  intolerância
alimentar
Resumo
Objetivos:  Avaliar  o  nível  de  calprotectina  fecal  em  neonatos  prematuros  com  intolerância
alimentar, além  de  avaliá-lo  como  um  indicador  de  intolerância  alimentar  e  determinar  um
nível de  corte  da  calprotectina  fecal  na  intolerância  alimentar.
Métodos:  Estudo  caso-controle  analítico,  realizado  em  um  multicentro  de  unidades  de  terapia
intensiva neonatais  no  Egito,  no  período  de  1◦ de  agosto  de  2014  a  1◦ de  marc¸o de  2015,  com
52 neonatos  prematuros.  Os  neonatos  foram  classiﬁcados  em  dois  grupos;  um  grupo  de  estudo
incluindo 26  neonatos  que  atenderam  aos  critérios  de  inclusão  e  um  grupo  de  controle  incluindo
26 neonatos  para  comparac¸ão.
Resultados:  Os  níveis  de  calprotectina  fecal  variaram  de  3,9  g/g  a  971,8  g/g  e  houve  um
aumento signiﬁcativo  da  calprotectina  fecal  no  grupo  de  estudo  quando  comparado  ao  grupo
de controle  (334,3  ±  236,6  g/g  em  comparac¸ão  a  42,0  ±  38,2  g/g,  respectivamente)  com
correlac¸ão inversa,  moderada  signiﬁcativa  entre  a  calprotectina  fecal  e  o  peso  ao  nascer.  Adi-
cionalmente,  houve  correlac¸ão  moderada  signiﬁcativa  entre  a  calprotectina  fecal  e  a  durac¸ão
do intervalo  de  amamentac¸ão.  Por  outro  lado,  não  houve  correlac¸ão  entre  a  calprotectina  fecal
e a  idade  pós-natal,  a  idade  gestacional  ou  o  volume  de  amamentac¸ão.  Foi  considerado  um
corte nos  níveis  de  67,0  g/g;  com  sensibilidade  de  100,0%  e  especiﬁcidade  de  76,9%.
Conclusão:  O  nível  de  calprotectina  fecal  aumentou  signiﬁcativamente  em  neonatos  com
intolerância  alimentar  e  podemos  utilizá-lo  para  detectar  casos  precoces  com  enterocolite
necrosante  em  neonatos,  porém  ainda  são  necessárias  mais  investigac¸ões  em  mais  pacientes.’
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um  artigo


























Feeding  of  preterm  neonates  is  one  of  the  main  challenges
faced  by  neonatal  practitioners,  especially  those  in  the  low
birth  weight  groups.1 Preterm  neonates  have  greater  mor-
tality  and  morbidity  with  long-term  disorders.2
Feeding  intolerance  is  known  as  a  difﬁculty  in  feeding
milk,  causing  a  change  in  the  usual  enteral  feeding  due
to  the  appearance  of  one  or  more  of  the  following  gas-
trointestinal  clinical  symptoms:  gastric  residuals,  vomiting,
abdominal  distention,  distended  bowel  loops,  and  change
in  character  of  stool.  Apnea,  bradycardia,  and  temperature
instability  are  also  included  as  symptoms  of  feeding  intoler-
ance,  but  only  for  the  reason  of  nursing  judgment,  in  order
to  give  guidance  on  detection  of  progression  to  more  serious
complications  such  as  necrotizing  enterocolitis  (NEC).3
Many  risk  factors  may  aggravate  feeding  intolerance,
including  poor  coordination  of  sucking  and  swallowing,  weak
lower  esophageal  sphincter,  small  stomach  capacity,  delayed
stomach  emptying  time,  and  intestinal  hypomotility4;  on  the
other  hand,  human  milk  is  the  best  for  neonates  and  forti-
ﬁers  derived  from  human  milk  act  as  a  good  substratum  for
preterm  infant  feeding.5
Abnormal  bacterial  colonization  may  be  a  factor  in  feed-
ing  intolerance  in  neonates,  mainly  due  to  dysfunction  of
the  intestinal  barrier,  the  immune  responses,  and  functions
of  the  intestine.  Abnormal  intestinal  colonization,  poor  bal-
ance  between  microbiota,  immune  response,  and  tolerance
mechanisms  may  result  in  feeding  intolerance  in  postnatal
life  and  also  in  gastrointestinal  disease  in  childhood.6
a
s
6In  1970,  Fagerhol  et  al.  searched  for  a  marker  of  leuko-
yte  turnover,  and  in  1980  they  published  their  discovery
f  a  protein  in  the  cytoplasm  of  neutrophils,  which  they
ermed  leukocyte-derived  L1  protein,  or  calprotectin.7 Cal-
rotectin  is  a  member  of  the  S100  family  of  calcium  and
inc  binding  proteins;  it  is  the  heterodimer  of  S100  A8/A9.
t  is  found  in  neutrophils,  monocytes,  and  some  squamous
pithelium  cells.  The  complex  accounts  for  up  to  60%  of
he  soluble  protein  content  of  the  neutrophil  cytoplasm.  It
s  released  by  activation  of  leucocytes  as  consequences  of
nﬂammatory  diseases.8 S100  A8  is  also  called  calgranulin  A
nd  myeloid-related  protein  8  (MRP8),  and  S100A9  is  called
algranulin  B  (MRP14).  They  both  are  linked  to  the  innate
mmune  system.9
Calprotectin  has  bacteriostatic  and  fungistatic  actions,
s  it  can  isolate  manganese  and  zinc  in  their  cells10; it  also
as  several  biological  properties  including  antimicrobic  and
munomodulatory  activity,  and  it  is  released  during  cell  acti-
ation  (active  release)  or  cell  death  (passive  release).11 It
as  been  suggested  as  a  useful  indicator  to  determine  the
everity  of  inﬂammation  in  the  intestine.12 The  most  signiﬁ-
ant  factors  that  affect  fecal  calprotectin  (FCP)  excretion
nclude  ante-  and  perinatal  antibiotic  treatment,  volume
f  enteral  feeding,  the  occurrence  of  unplanned  interrup-
ions  of  enteral  feeding,  and  the  gastrointestinal  bacterial
olonization.13
Several  studies  have  strongly  suggested  that  a  rise  in  FCP
bove  baseline  levels  may  be  a  candidate  for  a noninva-
ive  marker  of  gastrointestinal  diseases.14--17 FCP  levels  in
































































































The  present  study  aimed  to  assess  the  level  of  FCP  in
reterm  neonates  with  feeding  intolerance,  as  well  as  to
onﬁrm  it  as  a  marker  of  feeding  intolerance  and  to  deter-




nalytical  case--control  study
he  study  population  was  classiﬁed  into  two  groups:  Group  1
case  group)  included  preterm  infants  that  fulﬁlled  inclusion
riteria  and  showed  any  sign  of  feeding  intolerance.  Group
 (control  group)  included  postnatal  age-,  gestation-,  and
ex-matched  control  preterm  babies  who  did  not  show  signs
f  feeding  intolerance.
Inclusion  criteria:  Preterm  infants  of  both  genders  from
irth  until  the  28th  day  of  life  and  with  28  to  less  than  37
eeks  of  gestation,  admitted  to  the  neonatal  intensive  care
nit  (NICU),  who  showed  any  of  the  signs  of  feeding  intoler-
nce  leading  to  interruption  of  the  current  feeding  regime,
uch  as:  increased  gastric  residuals  (>50%)  of  the  previous
eeding,  emesis,  abdominal  distention  (increase  in  abdomi-
al  girth  by  2  cm  or  more  between  feedings),  bloody  stool,
iarrhea,  and  visible  bowel  loops.3
Exclusion  criteria:  Neonates  suffering  from  intestinal
ongenital  anomalies  or  neonates  with  sepsis.3
Sample  size:  The  following  equation  used  to  determine
he  required  sample  size:
 =  2(Z  +  Z)2 ×  P−Q−/(P1 −  P2)2
here:  N  =  number;  Z  =  the  value  of  standard  normal  dis-
ribution  for  type  I  error  probability  for  one  sided  test  and
qual  1.96  for  95%  signiﬁcance;  Z  =  the  value  of  standard
ormal  distribution  for  the  desired  statistical  power  of  90%
nd  equal  1.28  for  90%  power;  P− =  (P1 +  P2)/2;  Q− =  1  −  P−;
1 =  56%,  is  the  estimated  proportion  of  an  attribute  that
s  present  in  the  population1;  P2 =  prevalence  of  neonates
xpected  to  have  low  FCP  level  equals  5%.
According  to  the  calculation  the  sample  size  totaled  52
eonates:  26  neonates  from  each  group  who  were  admitted
o  the  NICU  in  the  period  between  the  1st  of  August,  2014
ntil  the  1st  of  March,  2015.
All  the  studied  neonates  were  subjected  to  history  tak-
ng,  full  clinical  examination,  and  investigations:  C-reactive
rotein,  complete  hemogram,  and  FCP.
FCP  was  measured  in  stool  using  the  Ridascreen  quantita-
ive  enzyme  linked  immunoassay  (Biopharm  AG,  Darmstadt,
ermany)
tatistical  analysis
he  collected  data  were  organized,  tabulated,  and  statis-
ically  analyzed  using  SPSS  version  16  (SPSS,  Inc.,  Chicago,
SA),  running  on  an  IBM  (International  Business  Machines,
ew  York,  USA)  compatible  computer.  Qualitative  data
categorical)  were  represented  as  relative  frequency  and
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hi-squared  (X2) was  used  as  a  test  of  comparison.  Quantita-
ive  data  were  represented  as  mean  and  standard  deviation
SD).  For  comparison  between  groups,  Student’s  t-test  for
ndependent  samples  was  used  for  normally  distributed
ata;  the  Mann--Whitney  (U)  test  was  used  for  non-normally
istributed  data.  For  correlation,  the  Pearson’s  correlation
oefﬁcient  (r)  was  used;  correlation  was  proportional  if  the
ign  was  positive;  inverse  if  the  sign  was  negative;  mild
f  <0.3;  moderate  if  0.3--0.7;  and  powerful  if  >0.7;  com-
lete  correlation  if  r  =  1.0;  and  no  correlation  whatsoever
f  r  =  0.0.  For  interpretation  of  results,  p-values  <  0.05  were
onsidered  signiﬁcant.
thical  consideration
thical  approval  of  the  study  was  obtained  from  the  research
thics  committee  of  the  faculty  of  medicine  of  the  Suez
anal  University  in  and  a  written  informed  parental  consent
lso  was  obtained.
esults
egarding  demographic  characteristics  (Table  1)
t  was  found  that  there  was  no  signiﬁcant  difference
etween  the  study  group  and  controls  regarding  sex  distri-
ution.  The  neonates  included  ranged  from  28  to  36  weeks
estation  and  there  was  no  signiﬁcant  difference  between
oth  groups  with  regards  to  gestational  age  (32.2  ±  2.7  vs.
2.3  ±  2.4  weeks,  respectively).  Their  birth  weight  ranged
rom  900  g  to  2750  g  and  there  was  no  signiﬁcant  differ-
nce  of  birth  weight  between  both  groups.  Regarding  the
ode  of  delivery;  11  cases  (21.2%)  were  delivered  by  nor-
al  vaginal  delivery  and  41  cases  (78.8%)  were  delivered  by
esarean  delivery;  there  was  no  signiﬁcant  difference  for
ormal  vaginal  delivery  in  this  study  when  compared  to  the
ontrol  group.  Post-natal  age  ranged  from  3rd  to  25th  days,
ith  a  non-signiﬁcant  increase  of  post-natal  days  in  the  study
roup  when  compared  to  the  control  group.
The  main  illness  in  the  study  and  control  groups  was
espiratory  distress  in  37  cases  (71.2%);  respiratory  distress
yndrome  (RDS)  in  ten  cases  (19.2%);  transient  tachypnea  of
ewborn  in  three  cases  (5.8%);  RDS  plus  hypoxic  ischemic
ncephalopathy  in  one  case  (1.9%);  and  persistent  pul-
onary  hypertension  of  newborn  (PPHN)  in  one  case  (1.9%);
here  were  no  signiﬁcant  differences  between  groups.
As  to  type  of  feeding;  it  was  exclusive  artiﬁcial  feed-
ng  in  41  cases  (78.8%);  exclusive  breast  feeding  in  one
ase  (1.9%)  and  mixed  (artiﬁcial  with  breast  feeding)  in
en  cases  (19.2%),  with  no  signiﬁcant  difference  between
roups.  Feeding  in  the  study  group  (volume/3  h)  ranged  from
 mL  to  30  mL  with  a  mean  of  18.4  ±  7.8  mL;  and  there  was
 non-signiﬁcant  decrease  of  feeding  volume  in  both  groups
Table  2).
The  presentation  of  feeding  intolerance  ranged  from
omiting  in  six  cases  (23.2%);  vomiting  and  abdominal
istension  in  ﬁve  cases  (19.2%);  residual  and  abdominal
istension  in  seven  cases  (26.9%);  abdominal  distension,
omiting,  apnea,  and  greenish  residual  in  ﬁve  cases  (19.2%);
omiting  with  residual  in  two  cases  (7.7%);  and  abdominal
istension,  vomiting,  residual,  and  delayed  gastric  emptying
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Table  1  Demographic  characteristics  in  study  and  control  groups.
Variable  Group  p-value
Study  (26)  Control  (26)
n  %  n  %
Sex
Male  11  42.3  14  53.8 0.41  (NS)
Female 15  57.7  12  46.2
Gestational  age  (weeks),  mean  ±  SD  32.2  ±  2.7  32.3  ±  2.4  0.91  (NS)
Birth weight  (g),  mean  ±  SD  1865.0  ±  548.0  1932.3  ±  459.5  0.63  (NS)
Postnatal age  (days),  mean  ±  SD  10.0  ±  5.7  8.3  ±  4.5  0.23  (NS)
Delivery mode
Normal  6  23.1  5  19.2 0.73  (NS)
CS 20  76.9  21  80.8
CS, cesarean section; NS, non-speciﬁc.
Table  2  Type  of  feeding  in  study  and  control  groups.
Variable  Group  p-value
Study  Control
n  %  n  %
Feeding
Artiﬁcial  20  76.9  21  80.8  0.49  (NS)
Breast feeding  1  3.8  0  0.0
Artiﬁcial +  BF  5  19.2  5  19.2










dBF, breast feeding; NS, non-speciﬁc.
in  one  case  (3.8%).  Altogether  ﬁve  cases  (9.6%)  with  Stage
IA  reported  to  have  NEC  in  the  study  group.
FCP  levels  ranged  from  3.9  g/g  to  971.8  g/g,  with  a  sig-
niﬁcant  increase  of  FCP  in  the  study  group  when  compared  to
the  control  group  (334.3  ±  236.6  g/g  vs.  42.0  ±  38.2  g/g,
respectively),  and  with  moderate  inverse  signiﬁcant  corre-
lation  between  FCP  and  birth  weight.  Furthermore,  there
was  moderate,  signiﬁcant  correlation  between  FCP  and  stop
feeding  duration.  Conversely,  there  was  no-signiﬁcant  cor-
relation  between  FCP  and  post-natal  age,  GA,  or  volume  of
feeding  (Table  3).
Analysis  of  ROC  curve  showed  that  the  area  under  the
curve  was  0.97  (this  reﬂected  higher  sensitivity);  for  the  best
cut-off,  values  with  the  best  sensitivity  were  chosen;  at  the
level  of  67.0  g/g,  the  sensitivity  was  100.0%  and  speciﬁcity





Table  3  Fecal  calprotectin  in  study  and  control  groups.
Group  Median  Mean  SD  
Study  273.85  334.33  236.61  
Control  23.95  42.03  38.23  
a Regarding FCP levels, because the data were non-normally distribut
was the appropriate test of comparison. However, there was a signiﬁca
control group (273.85 vs.  23.95).iscussion
eeding  intolerance  is  very  common  among  preterm  infants
n  enteral  feeds,  and  may  either  be  a  benign  sign  of  reduced
I  motility  or  may  be  an  initial  manifestation  of  necrotiz-
ng  enterocolitis  (NEC).  It  is  one  of  most  common  reasons
o  delay  advancement  of  enteral  feeds  or  for  suspension  of
eeds  in  preterm  infants.19 FCP  has  been  suggested  to  be  a
seful  marker  of  gastrointestinal  inﬂammation  in  neonates,
nd  has  also  been  raised  in  cases  of  inﬂammatory  bowel
isease.20
The  present  patients’  gestational  age  ranged  from  28
o  36  weeks,  with  mean  of  32.3  ±  2.6  weeks,  mean  birth
eight  of  1898.7  ±  501.9  g,  and  mean  postnatal  age  at  time
f  diagnosis  of  10.0  ±  5.7  days.  It  was  found  that  11  of  the
tudy  group  were  males  and  15  were  females.  In  the  study
Minimum  Maximum  U  p-value
67.30  971.80  20.0  <0.001a
3.90  126.10
ed, the median was the appropriate measure and Mann--Whitney
nt increase of median in the study group when compared to the
490  Moussa  R  et  al.
Table  4  Sensitivity  of  FCP  in  diagnosis  of  feeding  intolerance.
Positive  if  greater  than  or  equal  to  Sensitivity  Speciﬁcity  1  −  Speciﬁcity
59.70  1.000  0.731  0.269
67.05 1.000 0.769  0.231
72.15 0.962  0.769  0.231
79.65 0.962  0.808  0.192
Area under  the  curve  0.97




















































































y  Zoppelli  et  al.,21 they  found  that  the  mean  gestational
ge  (GA)  was  28.5  weeks  and  birth  weight  was  1057  g.  In
he  study  by  Albanna  et  al.,16 they  found  a  mean  GA  of
2  weeks,  a  mean  birth  weight  of  1500  g,  and  a  mean  age
t  diagnosis  of  9  days;  nine  were  boys  and  six  were  girls.
ui  and  Li14 had  a  mean  GA  of  30  weeks,  with  mean  age
t  diagnosis  of  12  days.  In  the  study  by  Carroll,22 samples
ere  obtained  (one  at  birth  and  the  other  on  the  3rd  day
fter  birth)  from  38  preterm  infants  with  GA  ranging  from
9  to  33  weeks.  Aydemir  et  al.17 found  mean  birth  weight
f  950  g,  and  a  mean  age  of  14  days  at  diagnosis.
Altogether,  41  neonates  were  exclusively  fed  artiﬁcially,
en  had  mixed  feeding,  and  only  one  case  was  exclusively
reast  fed,  unlike  the  study  by  Yoon,15 in  which  no  infants
ere  exclusively  breastfed.
The  present  study  found  no  signiﬁcant  correlation
etween  FCP  level  and  volume  of  enteral  feeding,  which
grees  with  Campeotto  et  al.23 and  differs  from  the  study  by
ang  et  al.,24 in  which  FCP  levels  decreased  with  increasing
nteral  feeding  volume  during  the  ﬁrst  month  of  postnatal
ife,  and  from  Josefesson  et  al.25 and  Rougé  et  al.,13 who
ound  that  FCP  increased  with  increasing  feeding  volume.
Previous  studies  have  researched  the  effect  of  the  type
f  feeding  on  the  level  of  FCP:  Campeotto  et  al.23 and  Yang
t  al.24 found  that  there  is  no  difference  in  the  FCP  levels
f  infants  fed  maternal  breast  milk  vs.  hydrolyzed  formula.
oon  et  al.15 found  that  there  was  no  effect  of  type  or
ethod  of  feeding  on  FCP,  while  Li  et  al.26 found  that  FCP
evel  was  higher  in  breast  fed  infants  than  in  formula  fed
nfants.  In  the  present  study  it  was  not  possible  to  examine
he  relationship  between  exclusively  breast  fed  and  exclu-
ively  formula  fed  infants,  as  there  was  only  one  exclusively
reast  fed  infant.
This  study  found  no  effect  of  gender  or  gestational  age  on
evel  of  FCP,  which  is  in  agreement  with  Campeoto  et  al.,23
nd  also  matches  with  Yang  et  al.24 and  Kapel  et  al.,18 but
s  in  disagreement  with  Rougé  et  al.,13 who  found  a  weak
egative  linear  relationship  between  FCP  and  gestational
ge.  Yoon  et  al.15 found  a  clear  positive  linear  relationship
etween  two  the  variables  (gestational  age  and  level  of  FCP)
n  newborns  born  at  <26  weeks  GA  and  a  distinctive  negative
inear  relationship  between  them  in  newborns  born  after  or
t  week  26  to  <30  weeks.
There  was  a  signiﬁcant  inverse  correlation  between  FCP
evel  and  birth  weight,  in  agreement  with  Laforgia  et  al.27
23nd  in  disagreement  with  Campeotto  et  al., who  found  no
igniﬁcant  relation  between  birth  weight  and  FCP.
In  the  present  study  there  was  a  signiﬁcant  posi-
ive  correlation  between  premature  rupture  of  membranes
a
a
iPROM)  and  level  of  FCP.  This  was  in  agreement  with  Cui
nd  Li.14
It  was  found  that  postnatal  age  has  no  signiﬁcant  correla-
ion  with  FCP  level;  this  was  in  agreement  with  Campeotto
t  al.23 and  in  disagreement  with  Josefesson  et  al.25 and
ougé  et  al.,13 who  observed  a  positive  relationship,  and
ang  et  al.,24 who  found  a  negative  relationship,  as  FCP
evels  tended  to  decrease  with  increasing  age.
There  was  no  correlation  between  mode  of  delivery  and
CP  level.  This  was  in  agreement  with  Laforgia  et  al.27 and
ougé  et  al.,13 and  in  disagreement  with  Josefesson  et  al.,25
ho  observed  positive  relationship  with  caesarian  section
CS)  delivery,  and  Cui  and  Li,14 who  observed  negative  rela-
ionship  with  CS  delivery.
In the  present  study  group,  four  preterm  infants  died  dur-
ng  the  time  of  study.  Twenty-six  preterm  were  found  to
ave  signs  of  feeding  intolerance;  ﬁve  of  them  (9.6%)  had
uspected  NEC  (bell’s  stage  IA);  all  of  them  have  recovered
ompletely  except  for  one  case  who  died  during  the  study.
n  the  study  by  Zoppelli  et  al.,21 9.2%  of  patients  devel-
ped  NEC  stage  II,  of  whom  ﬁve  had  fulminant  NEC.  Aydemir
t  al.17 observed  three  patients  with  mild  NEC  (Bell’s  stage
B),  four  with  deﬁnite  NEC  (Bell’s  stage  IIB),  and  three  with
linical  signs  consistent  with  advanced  NEC  (Bell’s  stage  IIIA
r  IIIB).
The  FCP  level  in  the  present  study  ranged  from  3.9  to
71.8  mg/kg,  with  a  mean  of  188.2  ±  223.5.  FCP  was  signif-
cantly  different  between  groups,  with  higher  FCP  levels  in
he  case  group,  which  was  in  agreement  with  Cui  et  al.,14
ho  stated  that  there  was  increased  FCP  level  in  the  group
ith  feeding  intolerance;  this  was  also  in  agreement  with
ougé  et  al.,13 who  stated  that  FCP  increased  in  preterm
ith  poor  tolerance  to  enteral  feeding.  Also,  this  ﬁnding
atched  with  Yang  et  al.,24 who  found  that  the  FCP  level
n  preterm  infants  rose  around  the  time  of  initial  signs  of
I  illness  and  decreased  as  these  signs  were  treated  and
esolved,  and  that  FCP  was  greater  among  those  with  NEC
ymptoms.
FCP  in  the  present  study  had  sensitivity  of  100%  and  speci-
city  of  76.9%  in  diagnosing  feeding  intolerance,  with  a  cut
ff  level  of  67.0  g/g,  which  is  lower  than  previous  studies
nd  with  better  sensitivity;  the  cut-off  level  in  Rougé  et  al.13
as  205  g/g.  Yang  et  al.24 studied  57  babies  with  very  low
irth  weight  and  found  that  FCP  >  350  g/g  stool  was  noted
ith  signs  of  gastrointestinal  injury,  such  as  bloody  stool
nd  bowel  perforation.  Additionally,  the  FCP  level  decreased
fter  initiation  of  treatments  in  sick  infants  who  recovered.
FCP  has  been  studied  in  gastrointestinal  disorders  in
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value  of  363  g/g  with  a  sensitivity  0.65  and  speciﬁcity  of
0.82  was  set  for  the  development  of  mild  digestive  symp-
toms,  and  a  cut-off  of  636  g/g  with  a  sensitivity  0.72  and
speciﬁcity  0.95  for  the  development  of  severe  symptoms.
Shenoy  et  al.28 showed  that  there  was  a  signiﬁcant  associ-
ation  between  high  FCP  and  NEC.  FCP  had  a  cut-off  value
≥280  g/g,  and  a  sensitivity  of  93.3%  and  speciﬁcity  of  39%.
The  present  study  demonstrated  that  there  was  a  cor-
relation  between  higher  FCP  levels  and  NEC  occurrence  in
the  case  group;  this  is  in  agreement  with  Albanna  et  al.,16
who  found  signiﬁcantly  higher  FCP  levels  in  neonates  who
developed  NEC,  with  maximum  level  in  neonates  with  Bell’s
stage  IIIb  (307.6  ±  4.1),  which  was  also  in  agreement  with
Aydemir  et  al.,17 who  found  that  raised  FCP  can  predict
the  occurrence  of  NEC,  as  mean  FCP  concentrations  in  NEC
cases  (185  mg/dL)  were  signiﬁcantly  higher  than  controls
(104  mg/dL).  Also,  they  found  that  there  was  a  signiﬁcant
positive  correlation  between  NEC  severity  and  FCP  level.
Yoon  et  al.15 also  found  that  FCP  concentration  was  higher
in  newborns  with  NEC  than  controls.  El  Fragy  et  al.29 showed
that  FCP  can  be  used  as  a  non-invasive  marker  for  early
prediction  of  NEC  in  neonates.
In  a  study  by  Thuijls  et  al.  that  involved  35  neonates  sus-
pected  of  NEC,  14  of  them  developed  NEC.  Median  of  FCP
levels  together  with  urinary  intestinal  fatty  acid  binding  pro-
tein  and  claudin-3  were  signiﬁcantly  higher  in  neonates  with
NEC  than  in  neonates  with  other  diagnoses,  with  a  cut-off
level  of  FCP  (286.2  g/g  feces).30 Carroll  et  al.  showed  that
FCP  was  markedly  elevated  --  with  a  mean  concentration  of
288.4  mg/L  --  in  patients  with  NEC,  compared  to  98.0  mg/L  in
controls.22 FCP  was  increased  to  >2000  g/g  in  three  cases  of
NEC  and  in  one  case  of  covered  perforation  with  microscopic
bowel  inﬂammation.25
All  of  the  52  studied  neonates  were  under  treatment  with
antibiotics,  so  we  were  not  able  to  identify  the  effect  of
postnatal  antibiotics  on  FCP  level.  Fecal  samples  were  not
always  easily  obtainable  in  infants  who  had  feeding  intoler-
ance,  as  they  had  delayed  gastric  emptying,  and  also  during
stop  feeding  duration  it  was  difﬁcult  to  take  a  stool  sample.
It  was  concluded  that  preterm  with  feeding  intolerance
had  statistically  signiﬁcant  elevated  levels  of  FCP  compared
to  preterm  infants  without  feeding  intolerance.
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